Publications by authors named "Wan-Ting Cao"
Background: Infliximab trough level (ITL) severely affects therapeutic outcomes of Crohn's disease (CD) patients under infliximab (IFX). Recently, frontier research has focused on identifying ITL based on different therapeutic targets. Although previous studies have elaborated clinical value of ITL monitoring on short-term outcomes in CD patients during therapy, studies contraposing the predictive value of ITL on long-term endoscopic outcomes in CD patients are still scarce domestically and overseas.
View Article and Find Full Text PDFArticle Synopsis
- Blood concentration of biologics plays a significant role in managing inflammatory bowel disease (IBD), but predicting outcomes based on these levels is complex and often disputed.
- A comprehensive review of 23 articles showed specific blood concentration ranges for biologics like infliximab and adalimumab that correlate with mucosal healing and fistula closure in IBD patients.
- The study concludes that while there are observed blood concentration thresholds for predicting endoscopic inactivity in IBD, relying solely on these levels can be misleading, highlighting the need for more precise therapeutic drug monitoring.